Efficacy and Safety of Baypure Vitamin C & Ferulic Acid Serum

A Single-Arm, Open-Label Clinical Study to Assess the Efficacy and Safety of Baypure Vitamin C & Ferulic Acid Serum in Enhancing Skin Brightness and Improving Overall Skin Health Parameters - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/10/096426

Enrollment

Registered

2025-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Vitamin C & Ferulic Acid Serum: Apply 5–6 drops applied topically on face and neck, twice daily. Duration: 4 weeks. Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males and females aged 18–45 years. 2. Subjects with dull and mildly pigmented skin. 3. Willingness to provide written informed consent. 4. Female participants of childbearing potential: negative urine pregnancy test at screening. 5. Willing to avoid excessive sun exposure during study duration. 6. Free from systemic or dermatological disorders that may interfere with results.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women or those planning pregnancy during the study. 2. History of skin cancers within the past 5 years. 3. Presence of active skin disease or open lesions or infections in the treatment area. 4. Known allergy to Vitamin C, Ferulic Acid, or excipients in the test product. 5. Use of systemic corticosteroids or immunosuppressive or biologic therapies within 90 days. 6. Participation in another interventional study within the past 90 days.

Design outcomes

Primary

Measure	Time frame
1. change in Skin Gloss or brightness 2. change in Skin Lightness 3. change in Pigmentation 4. change in Hydration 5. change in TEWL 6. Dark Spots by visioscan 7. Texture & Smoothness 8. DSLR ImagingTimepoint: At t0, t30min, t14days, t28days	—

Secondary

Measure	Time frame
SGATimepoint: At t28 days	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results